KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Current Deferred Revenue (2020 - 2025)

Historic Current Deferred Revenue for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $47.4 million.

  • Recursion Pharmaceuticals' Current Deferred Revenue fell 446.76% to $47.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.4 million, marking a year-over-year decrease of 446.76%. This contributed to the annual value of $61.8 million for FY2024, which is 6956.84% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Current Deferred Revenue of $47.4 million as of Q3 2025, which was down 446.76% from $39.7 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Current Deferred Revenue's 5-year high stood at $73.1 million during Q2 2023, with a 5-year trough of $10.0 million in Q1 2021.
  • In the last 5 years, Recursion Pharmaceuticals' Current Deferred Revenue had a median value of $44.0 million in 2023 and averaged $41.0 million.
  • Per our database at Business Quant, Recursion Pharmaceuticals' Current Deferred Revenue skyrocketed by 53781.0% in 2022 and then crashed by 5594.83% in 2024.
  • Quarter analysis of 5 years shows Recursion Pharmaceuticals' Current Deferred Revenue stood at $10.0 million in 2021, then soared by 467.26% to $56.7 million in 2022, then plummeted by 35.79% to $36.4 million in 2023, then skyrocketed by 69.57% to $61.8 million in 2024, then decreased by 23.32% to $47.4 million in 2025.
  • Its last three reported values are $47.4 million in Q3 2025, $39.7 million for Q2 2025, and $39.7 million during Q1 2025.